World Investment Advisors LLC Purchases 68,172 Shares of Edwards Lifesciences Co. (NYSE:EW)

World Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 1,660.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,277 shares of the medical research company's stock after purchasing an additional 68,172 shares during the period. World Investment Advisors LLC's holdings in Edwards Lifesciences were worth $4,770,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in EW. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at about $32,000. Avior Wealth Management LLC lifted its position in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after buying an additional 308 shares during the last quarter. Peoples Bank KS purchased a new position in shares of Edwards Lifesciences during the third quarter valued at $40,000. Finally, JFS Wealth Advisors LLC grew its stake in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after purchasing an additional 166 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Stifel Nicolaus lifted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a "hold" rating in a report on Thursday, December 5th. Robert W. Baird dropped their price target on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Morgan Stanley reissued an "equal weight" rating and issued a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Sanford C. Bernstein raised Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a report on Monday, October 28th. Finally, Piper Sandler dropped their price target on Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $78.65.

Edwards Lifesciences Stock Down 0.8 %

EW traded down $0.58 during midday trading on Friday, hitting $73.39. The company had a trading volume of 1,386,448 shares, compared to its average volume of 4,635,614. The company has a market capitalization of $43.29 billion, a price-to-earnings ratio of 10.67, a PEG ratio of 3.63 and a beta of 1.12. The stock's 50 day moving average price is $69.26 and its 200 day moving average price is $74.19. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences's revenue for the quarter was up 8.9% on a year-over-year basis. During the same period last year, the firm earned $0.59 EPS. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock valued at $2,323,150 in the last quarter. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.